Maraviroc
- Generic Name
- Maraviroc
- Brand Names
- Celsentri, Selzentry
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41F2N5O
- CAS Number
- 376348-65-1
- Unique Ingredient Identifier
- MD6P741W8A
- Background
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
- Indication
Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.
- Associated Conditions
- CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects
- Conditions
- HIV Infections
- Interventions
- Drug: Optimized Background Therapy (OBT)
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 190
- Registration Number
- NCT00098748
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
- Conditions
- HIV Infections
- Interventions
- Drug: optimized background therapy
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 474
- Registration Number
- NCT00098722
- Locations
- 🇬🇧
Pfizer Investigational Site, Newcastle Upon Tyre, United Kingdom
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2004-12-07
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 601
- Registration Number
- NCT00098306
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
- Conditions
- HIV-1
- Interventions
- First Posted Date
- 2004-12-07
- Last Posted Date
- 2013-10-09
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 916
- Registration Number
- NCT00098293
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- HIV Infections
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: atazanavir/ritonavir dosage #1Drug: tipranavir/ritonavirDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: darunavir/ritonavir dosage #3Drug: levoflaxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.